Morphine - .
Phase 3Small molecule
Morphine - . is one of 56 small molecule programs targeting Cesarean Section. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
83 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Dynastat
PfizerPreclinical
Proamatine
TakedaPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cesarean Section1 trial
Role of Prophylactic Antiemetics in Women Receiving Intrathecal Morphine and Lipophilic Opioids Added to Bupivacaine for Cesarean Section
Not yet recruiting·—·Phase 4·NCT06704139·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Morphine - .. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRambam Health Care Campus